Exploring new treatments for breast and ovarian cancer using epigenetic therapy and PARP inhibitors
Official title: Linking Epigenetic-Therapy Induction of Inflammasome Signaling to Generation of a BRCAness Phenotype
Funded at Coriell Institute for Medical Research · NIH-10886791 · Data updated 2026-11-12
This study is looking at how a new combination of cancer treatments might work better for people with breast and ovarian cancer, even if they don't have a specific gene mutation, by boosting the body's immune response to help the therapy be more effective.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Coriell Institute for Medical Research NIH-funded |
| Lab location | 1 site (Camden, United States) |
| Project start | August 16, 2021 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $401,744 |
| NIH project number | 5P50CA254897-04 |
| Project ID | NIH-10886791 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with breast or ovarian cancer, particularly those with triple-negative breast cancer or those who are BRCA proficient.
✕Less likely to help
Patients with cancers that are not breast or ovarian, or those who have already exhausted all treatment options, may not benefit from this research.
What this research studies
This research investigates how combining a hypomethylating agent with a novel PARP inhibitor can enhance cancer treatment for patients with breast and ovarian cancer, regardless of their BRCA mutation status. The approach focuses on inducing inflammasome signaling to create a BRCAness phenotype, which may improve the effectiveness of the therapy. The study includes both preclinical and clinical phases, aiming to expand the benefits of PARP inhibitors to a broader patient population. Patients will be monitored through correlative analyses of serial samples to understand the mechanisms behind treatment responses.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for breast and ovarian cancer patients who do not have BRCA mutations.
How similar studies have gone: Other research has shown promising results with similar approaches, particularly in enhancing the efficacy of PARP inhibitors in cancer treatment.
Where this research is happening
-
Coriell Institute for Medical Research
Camden, United States Active
Researchers
- Principal investigator: Nephew, Kenneth P — Coriell Institute for Medical Research
- Study coordinator: Nephew, Kenneth P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.